| Old Articles: <Older 8611-8617 |
|---|
 |
Chemistry World
March 27, 2013
Eugene Gerden |
Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs.   |
Pharmaceutical Executive
March 1, 2013 |
China and the Emerging Markets Challenge: Why Big Pharma Must Embrace a New Strategy With health reform already tagged as a key domestic priority, their policies will pose new opportunities and challenges for Big Pharma companies active in China. |
Pharmaceutical Executive
March 1, 2013
Ben Comer |
Brand of the Year: Januvia When Merck's Januvia received its first regulatory approval, in Mexico in 2006, no one predicted its long-term success. In 2012, the company's diabetes franchise became the highest-selling product family in Merck's 122-year history. |
Pharmaceutical Executive
March 1, 2013
Ken Getz |
Building Clinical Trial Awareness for Patients: Why Not Try the Pharmacist? The author explains how building a stakeholder outreach agenda around the community pharmacist can lead to a better outcome in managing the complex ins and outs of a trial protocol. |
Pharmaceutical Executive
March 1, 2013
Sillup et al. |
Back in the News Big Pharma takes a fresh licking in our latest audit of US press coverage of business and policy issues. |
Pharmaceutical Executive
March 1, 2013
Desai & Anbil |
Specialty Service Programs: Gearing up for Next Generation Technologies Innovation in hub program design for patient scrip data and clinical support services can lead to increased market share in the hotly contested specialty medicine space. |
Pharmaceutical Executive
March 1, 2013
Jill Wechsler |
Another Round of FDA Legislation? Pressure for action on key enforcement and regulatory issues may prompt congressional action this year. |
| <Older 8611-8617 Return to current articles. |
